“The completion of our FREEDOM-CVO safety trial is the most recent of four consecutive and successful clinical milestones for Intarcia, marking the end of our large pivotal Phase 3 trials required for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果